From Failed Psychiatrist To $149-Million Fraud: Indian-Origin Man's Trail Of Scandal In US
Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ethical and legal storms that followed.
Indian-origin doctor Tonmoy Sharma was arrested in the United States for allegedly masterminding a $149-million healthcare fraud. The 58-year-old was taken into custody at Los Angeles International Airport as he was allegedly preparing to flee to Dubai.
Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ethical and legal storms that followed.
Tonmoy Sharma first rose to prominence in the 1990s for conducting clinical trials for major pharmaceutical companies in the UK. But his reputation began to unravel in 2001 when concerns were raised about irregularities in a £250,000 study comparing Sanofi's antipsychotic drug Amisulpride with a rival from Eli Lilly.
Sanofi launched a private investigation after their medical adviser, Catherine Baxter, flagged discrepancies in Tonmoy Sharma's work. The probe uncovered a series of ethics violations which included fabricated approvals from ethics committees, recruitment of vulnerable patients without proper consent, financial incentives to encourage participation and false academic claims including a non-existent professorship and doctorate.
In 2007, after multiple complaints and an investigation by the UK's General Medical Council, Tonmoy Sharma's medical licence was revoked. He was found guilty of serious professional misconduct after which he moved to the United States.
Allegations In The US
In California, Tonmoy Sharma established Sovereign Health Group, which rapidly grew into a prominent network of addiction treatment centres. Since 2017, Sovereign has been under investigation by the FBI for suspected fraud. In 2018, federal agents raided the group's headquarters in San Clemente, several treatment centres and Tonmoy Sharma's residence in San Juan Capistrano.
Though Sovereign shut down that year, Tonmoy Sharma continued operating under a new name- Dana Shores Recovery- using a different license to stay under the radar.
According to the federal indictment, Tonmoy Sharma and his associates submitted more than $149 million in fraudulent insurance claims and received at least $21 million in illegal kickbacks for patient referrals. He now faces four counts of wire fraud, one count of conspiracy, and three counts of receiving illegal remunerations.
If convicted, Tonmoy Sharma could face up to 20 years in prison for each wire fraud charge, five years for conspiracy, and 10 years for each kickback-related offense.
About the Author
Mallika Soni
Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated!
First Published:
June 05, 2025, 20:53 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 days ago
- Time of India
Trump pressures 17 pharma CEOs to cut US drug prices
Donald Trump has asked major pharmaceutical companies to lower US drug prices. He wants them to match the prices paid in other countries. Trump sent letters to companies like Eli Lilly and Pfizer. He wants them to offer the best prices to Medicaid patients. Trump has given the companies time until September 29 to respond. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca , among others, the White House said."Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry," Trump wrote in the letters, copies of which were posted on his Truth Social of Pfizer , Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation gave companies until September 29 to respond with binding commitments to those terms."If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices," he lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices."I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.," said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it "just another shot in the dark."Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants.U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. "Our discussions have been productive," she said.
Time of India
4 days ago
- Time of India
Donald Trump's crackdown at pharma: 'Americans need lower drug prices'; sets 29 September deadline or face action
US President Donald Trump issued a sharp warning to pharmaceutical giants, calling on them to slash prescription drug prices in the United States or face the consequences. In letters addressed to 17 major drug companies, Trump urged them to cooperate with his administration to implement sweeping reforms aimed at lowering costs for American patients, who currently pay some of the highest drug prices in the developed world. These firms are Eli Lilly and Company, Sanofi, Regeneron Pharma, Merek, GSK, Johnson & Johnson, Genentech, Amgen, AstraZeneca, Novo Nordisk, Pfizer, EMD Serono, Gilead Sciences, Novartis, Bristol Myers Squibb, Boehringer Ingelheim, AbbVie. 'If you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,' Trump wrote in the letters, which were published on his platform, Truth Social. The push follows an executive order Trump signed on May 12, 2025, titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. The order is designed to end what Trump called 'global freeloading' by foreign governments benefiting from lower prices on American-developed medicines. According to the White House, drug prices in the US are on average up to three times higher than in other developed countries for the same medications. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Learn More Undo Trump has blamed this on 'an unacceptable burden on hardworking American families' and vowed to put a stop to it. In the letters, Trump said that most proposals his administration had received from the pharmaceutical industry offered 'more of the same: shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry.' Instead, he laid out a clear list of demands to be fulfilled within 60 days: Extend most-favored-nation (MFN) pricing to Medicaid: Offer the full portfolio of existing drugs at MFN rates to all Medicaid patients. Guarantee MFN pricing for newly launched drugs: Ensure MFN pricing applies to Medicare, Medicaid and commercial payers for all new drugs at launch and beyond. Return increased revenues from abroad to American patients and taxpayers: Trump said domestic MFN pricing should push drug makers to negotiate tougher deals with foreign buyers, and the extra revenue must be used to lower domestic costs. Enable direct purchasing at MFN pricing: Adopt direct-to-consumer and direct-to-business distribution for widely used prescription drugs, allowing Americans access to the same low prices typically reserved for third-party payers. 'My team, including secretary Kennedy and Administrator Oz, stand ready to implement these terms,' Trump said. 'I expect you to further engage with them immediately, in good faith, to deliver relief for American families.' The US President highlighted achieving global price parity would be the most effective outcome for all stakeholders, but he warned that failure to comply would prompt government action. 'Americans are demanding lower drug prices and they need them today,' he added. 'Other nations have been freeloading on US innovation for far too long; it is time they pay their fair share.' He concluded the letter by asking for binding commitments by September 29, and promised support for implementation queries. The move marks one of Trump's most aggressive attempts to tackle the long-standing issue of inflated prescription drug prices in the United States. Stay informed with the latest business news, updates on bank holidays and public holidays . Discover stories of India's leading eco-innovators at Ecopreneur Honours 2025
&w=3840&q=100)
Business Standard
23-07-2025
- Business Standard
US bans flu shots with thimerosal in RFK Jr led vaccine policy shift
The United States will stop distributing all influenza vaccines that contain mercury-based preservative thimerosal, marking the latest move by US Health Secretary Robert F. Kennedy Jr. to reshape vaccine policy. Last month, a vaccine panel with members handpicked by Kennedy voted in favor of Americans receiving seasonal flu shots that are free from thimerosal, despite decades of studies showing no related safety issues. About 5 per cent of flu shots given in the US in the last flu season were multi-dose vials that contained the preservative, which was largely phased out decades ago. Anti-vaccine groups have for decades linked thimerosal to autism and other neurodevelopmental disorders, and Kennedy wrote a book in 2014 in which he advocated for "the immediate removal of mercury" from vaccines. The FDA on its website says "there was no evidence that thimerosal in vaccines was dangerous," and that the decision to remove it previously was a precautionary measure to decrease overall exposure to mercury among young infants. One of the panelists, who voted against the recommendation, had pointed out that the risk of not receiving the influenza vaccine because it contains thimerosal is greater than any known risks of the preservative. CSL's Afluria, and Flucelvax and Sanofi's Fluzone include thimerosal in multi-dose versions, according to the FDA's website. Kennedy accepted the panel's recommendation, the Department of Health and Human Services said on Wednesday, in the absence of the CDC director, who typically signs off on them before they are implemented. President Donald Trump's nominee for the CDC director, Susan Monarez, is yet to be confirmed by the US Senate. Other recommendations made by the panel, known as the Advisory Committee for Immunization Practices, at a meeting in June are still under review, the HHS said. Vaccine manufacturers have confirmed that they have the capacity to replace multi-dose vials containing the preservative, ensuring that supplies will not be interrupted, HHS said. Sanofi said it acknowledges the new policy and will have sufficient supply of the flu vaccine this season. CSL did not immediately respond to a Reuters request for comment.
